Section: Partnerships and Cooperations

European Initiatives

FP7 & H2020 Projects

The Drug Disease Model Resources (DDMoRe) consortium will build and maintain a universally applicable, open source, model-based framework, intended as the gold standard for future collaborative drug and disease modeling and simulation.

The DDMoRe project is supported by the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the European Union and the pharmaceutical industry association EFPIA.

Marc Lavielle was leader of WP6: "New tools for Model Based Drug Development".

DDMoRe website: http://www.ddmore.eu

Duration: 2010 - 2016

Project members: Uppsala Universitet, Sweden; University of Navarra, Spain; Universiteit Leiden, Netherlands; Université Paris Diderot, France; Universita degli Studi di Pavia, Italy; UCB Pharma , Belgium; Simcyp, UK; Pfizer, UK; Optimata , Israel; Novo Nordisk , Denmark; Novartis, Switzerland; Merck Serono, Switzerland; Takeda, Switzerland; Mango Business Solutions , UK; Lixoft, France; Interface Europe, Belgium; Institut de Recherches Internationales Servier, France; Inria, France; GlaxoSmithKline Research and Development, UK; Freie Universitat Berlin, Germany; F. Hoffmann - La Roche , Switzerland; EMBL - European Bioinformatics Institute, UK; Eli Lilly , UK; Cyprotex Discovery, UK; Consiglio Nazionale delle Ricerche, Italy; AstraZeneca, Sweden.